Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer: Miniperspective

Journal of Medicinal Chemistry

Volumn 59, Issue 14, 2016, Pages 6580-6594

  Song, Zhendong ^a   Ge, Yang ^a   Wang, Changyuan ^a   Huang, Shanshan ^a   Shu, Xiaohong ^a   Liu, Kexin ^a   Zhou, Youwen ^b   Ma, Xiaodong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANILINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; METHIONINE; MUTANT PROTEIN; OSIMERTINIB; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; ROCILETINIB; THREONINE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER RESISTANCE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; IC50; MUTATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PHYSICOCHEMICAL MODEL; REVIEW; STRUCTURE ACTIVITY RELATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MODEL; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHARMACOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PYRIDONES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84978657458     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00840     Document Type: Review

References (84)

1. Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012 Ca-Cancer J. Clin. 2015, 65, 87-108 10.3322/caac.21262
2. Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics Ca-Cancer J. Clin. 2015, 65, 5-29 10.3322/caac.21254
3. Pallis, A. G.; Serfass, L.; Dziadziuszko, R.; van Meerbeeck, J. P.; Fennell, D.; Lacombe, D.; Welch, J.; Gridelli, C. Targeted therapies in the treatment of advanced/metastatic NSCLC Eur. J. Cancer 2009, 45, 2473-2487 10.1016/j.ejca.2009.06.005
4. Vansteenkiste, J. F.; Schildermans, R. H. The future of adjuvant chemotherapy for resected non-small cell lung cancer Expert Rev. Anticancer Ther. 2005, 5, 165-175 10.1586/14737140.5.1.165
5. Hirsch, F. R.; Varella-Garcia, M.; Bunn, P. A., Jr.; Di Maria, M. V.; Veve, R.; Bremmes, R. M.; Barón, A. E.; Zeng, C.; Franklin, W. A. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J. Clin. Oncol. 2003, 21, 3798-3807 10.1200/JCO.2003.11.069
6. Ohsaki, Y.; Tanno, S.; Fujita, Y.; Toyoshima, E.; Fujiuchi, S.; Nishigaki, Y.; Ishida, S.; Nagase, A.; Miyokawa, N.; Hirata, S.; Kikuchi, K. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol. Rep. 2000, 7, 603-607 10.3892/or.7.3.603
7. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 2007, 7, 169-181 10.1038/nrc2088
8. de Mello, R. A.; Pires, F. S.; Marques, D. S.; Oliveira, J.; Rodrigues, A.; Soares, M.; Azevedo, I.; Peixoto, A.; Santos, C.; Pinto, C.; Hespanhol, V.; Teixeira, M. R.; Amaro, T.; Queiroga, H.; Araújo, A. EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a portuguese retrospective study Tumor Biol. 2012, 33, 2061-2068 10.1007/s13277-012-0465-5
9. Cohen, M. H.; Williams, G. A.; Sridhara, R.; Chen, G.; Pazdur, R. FDA drug approval summary gefitinib (ZD1839) (Iressa) tablets Oncologist 2003, 8, 303-306 10.1634/theoncologist.8-4-303
10. Dowell, J.; Minna, J. D.; Kirkpatrick, P. Erlotinib hydrochloride Nat. Rev. Drug Discovery 2005, 4, 13-14 10.1038/nrd1612
11. Bonomi, P. Erlotinib: A new therapeutic approach for non-small cell lung cancer Expert Opin. Invest. Drugs 2003, 12, 1395-1401 10.1517/13543784.12.8.1395
12. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007, 11, 217-227 10.1016/j.ccr.2006.12.017
13. Carey, K. D.; Garton, A. J.; Romero, M. S.; Kahler, J.; Thomson, S.; Ross, S.; Park, F.; Haley, J. D.; Gibson, N. M.; Sliwkowski, M. X. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib Cancer Res. 2006, 66, 8163-8171 10.1158/0008-5472.CAN-06-0453
14. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jänne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2005, 352, 786-792 10.1056/NEJMoa044238
15. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2004, 350, 2129-2139 10.1056/NEJMoa040938
16. Engelman, J. A.; Jänne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin. Cancer Res. 2008, 14, 2895-2899 10.1158/1078-0432.CCR-07-2248
17. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 10.1371/journal.pmed.0020073
18. Balak, M. N.; Gong, Y.; Riely, G. J.; Somwar, R.; Li, A. R.; Zakowski, M. F.; Chiang, A.; Yang, G.; Ouerfelli, O.; Kris, M. G.; Ladanyi, M.; Miller, V. A.; Pao, W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin. Cancer Res. 2006, 12, 6494-6501 10.1158/1078-0432.CCR-06-1570
19. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 2002, 277, 46265-46272 10.1074/jbc.M207135200
20. Michalczyk, A.; Klüter, S.; Rode, H. B.; Simard, J. R.; Grütter, C.; Rabiller, M.; Rauh, D. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR Bioorg. Med. Chem. 2008, 16, 3482-3488 10.1016/j.bmc.2008.02.053
21. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 2070-2075 10.1073/pnas.0709662105
22. Sequist, L. V.; Besse, B.; Lynch, T. J.; Miller, V. A.; Wong, K. K.; Gitlitz, B.; Eaton, K.; Zacharchuk, C.; Freyman, A.; Powell, C.; Ananthakrishnan, R.; Quinn, S.; Soria, J. C. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 2010, 28, 3076-3083 10.1200/JCO.2009.27.9414
23. Sos, M. L.; Rode, H. B.; Heynck, S.; Peifer, M.; Fischer, F.; Klüter, S.; Pawar, V. G.; Reuter, C.; Heuckmann, J. M.; Weiss, J.; Ruddigkeit, L.; Rabiller, M.; Koker, M.; Simard, J. R.; Getlik, M.; Yuza, Y.; Chen, T. H.; Greulich, H.; Thomas, R. K.; Rauh, D. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation Cancer Res. 2010, 70, 868-874 10.1158/0008-5472.CAN-09-3106
24. Kim, Y.; Ko, J.; Cui, Z.; Abolhoda, A.; Ahn, J. S.; Ou, S. H.; Ahn, M. J.; Park, K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor Mol. Cancer Ther. 2012, 11, 784-791 10.1158/1535-7163.MCT-11-0750
25. Soria, J. C.; Sequist, L. V.; Goldman, J. W.; Wakelee, H. A.; Neal, J.; Camidge, R.; Gadgeel, S. M.; Papadimitrakopoulou, V.; Dziadziuszko, R.; Piotrowska, Z.; Varga, A.; Solomon, B. J. Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M Ann. Oncol. 2015, 26, ii4
26. Sequist, L. V.; Soria, J. C.; Goldman, J. W.; Wakelee, H. A.; Gadgeel, S. M.; Varga, A.; Papadimitrakopoulou, V.; Solomon, B. J.; Oxnard, G. R.; Dziadziuszko, R.; Aisner, D. L.; Doebele, R. C.; Galasso, C.; Garon, E. B.; Heist, R. S.; Logan, J.; Neal, J. W.; Mendenhall, M. A.; Nichols, S.; Piotrowska, Z.; Wozniak, A. J.; Raponi, M.; Karlovich, C. A.; Jaw-Tsai, S. S.; Isaacson, J.; Despain, D.; Matheny, S. L.; Rolfe, L.; Allen, A. R.; Camidge, D. R. Rociletinib in EGFR-mutated non-small-cell lung cancer N. Engl. J. Med. 2015, 372, 1700-1709 10.1056/NEJMoa1413654
27. Lai, M.; Witowski, S. R.; Tester, R. W.; Lee, K. Salts of an epidermal growth factor receptor kinase inhibitor. WO2013138502A1, 2013.
28. Yang, J. C. H.; Popat, S.; Georgiou, P.; Miyamoto, E.; Isaacson, J. D.; Wakelee, H. A. A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. Presented at the ASCO Annual Meeting, Chicago, IL, May 29-June 2, 2015; Abstract TPS8109.
29. Lai, M. Solid forms of an epidermal growth factor receptor kinase inhibitor. US9056839B2, 2015.
30. Walter, A. O.; Sjin, R. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovskiy, A.; Labenski, M.; Zhu, Z.; Wang, Z.; Sheets, M.; St Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; Van Dyke, T.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Discovery of a mutant selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discovery 2013, 3, 1404-1415 10.1158/2159-8290.CD-13-0314
31. Cross, D. A.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Red Brewer, M.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H.; Cantarini, M.; Kim, D. W.; Ranson, M. R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discovery 2014, 4, 1046-1061 10.1158/2159-8290.CD-14-0337
32. Jänne, P. A.; Yang, J. C. H.; Kim, D. W.; Planchard, D.; Ohe, Y.; Ramalingam, S. S.; Ahn, M. J.; Kim, S. W.; Su, W. C.; Horn, L.; Haggstrom, D.; Felip, E.; Kim, J. H.; Frewer, P.; Cantarini, M.; Brown, K. H.; Dickinson, P. A.; Ghiorghiu, S.; Ranson, M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N. Engl. J. Med. 2015, 372, 1689-1699 10.1056/NEJMoa1411817
33. Butterworth, S.; Finlay, M. R. V.; Ward, R. A.; Kadambar, V. K.; Chandrashekar, R.; Murugan, A.; Redfearn, H. M. Preparation of 2-(2,4,5-substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer. WO2013014448A1, 2013.
34. Jiang, T.; Zhou, C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer Transl. Lung Cancer Res. 2014, 3, 370-372 10.3978/j.issn.2218-6751.2014.08.02
35. Finlay, M. R. V.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A. E; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G. B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H. L.; Mellor, M. J.; Orme, J. P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M. J.; Whittaker, D.; Wells, S.; Wrigley, G. L. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor J. Med. Chem. 2014, 57, 8249-8267 10.1021/jm500973a
36. Lee, C. C.; Shiao, H. Y.; Wang, W. C.; Hsieh, H. P. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer Expert Opin. Invest. Drugs 2014, 23, 1333-1348 10.1517/13543784.2014.928283
37. Liao, B. C.; Lin, C. C.; Yang, C. H. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer Curr. Opin. Oncol. 2015, 27, 94-101 10.1097/CCO.0000000000000164
38. Cui, J. J. A new challenging and promising era of tyrosine kinase inhibitors ACS Med. Chem. Lett. 2014, 5, 272-274 10.1021/ml500091p
39. Worley, S. Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment Pharmacol. Ther. 2014, 39, 698-703
40. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Jänne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074 10.1038/nature08622
41. Chang, S.; Zhang, L.; Xu, S.; Luo, J.; Lu, X.; Zhang, Z.; Xu, T.; Liu, Y.; Tu, Z.; Xu, Y.; Ren, X.; Geng, M.; Ding, J.; Pei, D.; Ding, K. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790→methionine790 mutant J. Med. Chem. 2012, 55, 2711-2723 10.1021/jm201591k
42. Steuer, C. E.; Khuri, F. R.; Ramalingam, S. S. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer Cancer 2015, 121, E1-E6 10.1002/cncr.29139
43. Juchum, M.; Günther, M.; Laufer, S. A. Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors Drug Resist. Updates 2015, 20, 12-28 10.1016/j.drup.2015.05.002
44. Johnston, J. B.; Navaratnam, S.; Pitz, M. W.; Maniate, J. M.; Wiechec, E.; Baust, H.; Gingerich, J.; Skliris, G. P.; Murphy, L. C.; Los, M. Targeting the EGFR pathway for cancer therapy Curr. Med. Chem. 2006, 13, 3483-3492 10.2174/092986706779026174
45. Ward, R. A.; Anderton, M. J.; Ashton, S.; Bethel, P. A.; Box, M.; Butterworth, S.; Colclough, N.; Chorley, C. G.; Chuaqui, C.; Cross, D. A. E; Dakin, L. A.; Debreczeni, J. é.; Eberlein, C.; Finlay, M. R. V.; Hill, G. B.; Grist, M.; Klinowska, T. C. M.; Lane, C.; Martin, S.; Orme, J. P.; Smith, P.; Wang, F.; Waring, M. J. Structure and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) J. Med. Chem. 2013, 56, 7025-7048 10.1021/jm400822z
46. Fukumura, D.; Kashiwagi, S.; Jain, R. K. The role of nitric oxide in tumour progression Nat. Rev. Cancer 2006, 6, 521-534 10.1038/nrc1910
47. Bonavida, B.; Baritaki, S.; Huerta-Yepez, S.; Vega, M. I.; Chatterjee, D.; Yeung, K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 2008, 19, 152-157 10.1016/j.niox.2008.04.018
48. Aguirre, G.; Boiani, M.; Cerecetto, H.; Fernández, M.; González, M.; León, E.; Pintos, C.; Raymondo, S.; Arredondo, C.; Pacheco, J. P.; Basombrío, M. A. Furoxan derivatives as cytotoxic agents: Preliminary in vivo antitumoral activity studies Pharmazie 2006, 61, 54-59
49. Han, C.; Huang, Z.; Zheng, C.; Wan, L.; Zhang, L.; Peng, S.; Ding, K.; Ji, H.; Tian, J.; Zhang, Y. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer J. Med. Chem. 2013, 56, 4738-4748 10.1021/jm400463q
50. Han, C.; Huang, Z.; Zheng, C.; Wan, L.; Lai, Y.; Peng, S.; Ding, K.; Ji, H.; Zhang, Y. Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors Eur. J. Med. Chem. 2013, 66, 82-90 10.1016/j.ejmech.2013.05.026
51. Han, C.; Wan, L.; Ji, H.; Ding, K.; Huang, Z.; Lai, Y.; Peng, S.; Zhang, Y. Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors Eur. J. Med. Chem. 2014, 77, 75-83 10.1016/j.ejmech.2014.02.032
52. 8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations J. Med. Chem. 2012, 55, 10685-10699 10.1021/jm301365e
53. Zhou, W.; Ercan, D.; Jänne, P. A.; Gray, N. S. Discovery of selective irreversible inhibitors for EGFR-T790M Bioorg. Med. Chem. Lett. 2011, 21, 638-643 10.1016/j.bmcl.2010.12.036
54. Behenna, D. C.; Cheng, H.; Cho-Schultz, S.; Johnson, T. O., Jr.; Kath, J. C.; Nagata, A.; Nair, S. K.; Planken, S. P. 2,6-Substituted purine derivatives and their use in the treatment of proliferative disorders. WO2015075598 Al, 2015.
55. Abdel-Magid, A. F. Inhibitors of the epidermal growth factor receptor (EGFR) may provide effective treatment for lung adenocarcinoma ACS Med. Chem. Lett. 2015, 6, 732-733 10.1021/acsmedchemlett.5b00231
56. Xu, T.; Zhang, L.; Xu, S.; Yang, C. Y.; Luo, J.; Ding, F.; Lu, X.; Liu, Y.; Tu, Z.; Li, S.; Pei, D.; Cai, Q.; Li, H.; Ren, X.; Wang, S.; Ding, K. Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants Angew. Chem., Int. Ed. 2013, 52, 8387-8390 10.1002/anie.201302313
57. Xu, S.; Xu, T.; Zhang, L.; Zhang, Z.; Luo, J.; Liu, Y.; Lu, X.; Tu, Z.; Ren, X.; Ding, K. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties J. Med. Chem. 2013, 56, 8803-8813 10.1021/jm4012388
58. Zhou, W.; Liu, X.; Tu, Z.; Zhang, L.; Ku, X.; Bai, F.; Zhao, Z.; Xu, Y.; Ding, K.; Li, H. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant J. Med. Chem. 2013, 56, 7821-7837 10.1021/jm401045n
59. Wurz, R. P.; Pettus, L. H.; Ashton, K.; Brown, J.; Chen, J. J.; Herberich, B.; Hong, F. T.; Hu-Harrington, E.; Nguyen, T.; St. Jean, D. J., Jr.; Tadesse, S.; Bauer, D.; Kubryk, M.; Zhan, J.; Cooke, K.; Mitchell, P.; Andrews, K. L.; Hsieh, F.; Hickman, D.; Kalyanaraman, N.; Wu, T.; Reid, D. L.; Lobenhofer, E. K.; Andrews, D. A.; Everds, N.; Guzman, R.; Parsons, A. T.; Hedley, S. J.; Tedrow, J.; Thiel, O. R.; Potter, M.; Radinsky, R.; Beltran, P. J.; Tasker, A. S. Oxopyrido[2,3-d]pyrimidines as covalent L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors ACS Med. Chem. Lett. 2015, 6, 987-992 10.1021/acsmedchemlett.5b00193
60. T790M mutant MedChemComm 2015, 6, 1693-1697 10.1039/C5MD00208G
61. 790 mutant MedChemComm 2012, 3, 1155-1159 10.1039/c2md20078c
62. Hanan, E. J.; Eigenbrot, C.; Bryan, M. C.; Burdick, D. J.; Chan, B. K.; Chen, Y.; Dotson, J.; Heald, R. A.; Jackson, P. S.; La, H.; Lainchbury, M. D.; Malek, S.; Purkey, H. E.; Schaefer, G.; Schmidt, S.; Seward, E. M.; Sideris, S.; Tam, C.; Wang, S.; Yeap, S. K.; Yen, I.; Yin, J.; Yu, C.; Zilberleyb, I.; Heffron, T. P. Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation J. Med. Chem. 2014, 57, 10176-10191 10.1021/jm501578n
63. Wu, C. H.; Coumar, M. S.; Chu, C. Y.; Lin, W. H.; Chen, Y. R.; Chen, C. T.; Shiao, H. Y.; Rafi, S.; Wang, S. Y.; Hsu, H.; Chen, C. H.; Chang, C. Y.; Chang, T. Y.; Lien, T. W.; Fang, M. Y.; Yeh, K. C.; Chen, C. P.; Yeh, T. K.; Hsieh, S. H.; Hsu, J. T. A; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and Michael acceptor group for maximal potency J. Med. Chem. 2010, 53, 7316-7326 10.1021/jm100607r
64. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711 10.1038/onc.2008.109
65. Hirsh, V. Afatinib (BIBW 2992) development in non-small-cell lung cancer Future Oncol. 2011, 7, 817-825 10.2217/fon.11.62
66. Hirsh, V. Next-generation covalent irreversible kinase inhibitors in NSCLC: focus on afatinib BioDrugs 2015, 29, 167-183 10.1007/s40259-015-0130-9
67. Schwab, C. L.; Roque, D. M.; English, D. P.; Bellone, S.; Lopez, S.; Cocco, E.; Nicoletti, R.; Bortolomai, I.; Bonazzoli, E.; Ratner, E.; Silasi, D.-A.; Azodi, M.; Schwartz, P. E.; Rutherford, T. J.; Santin, A. D. Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo Gynecol. Oncol. 2015, 136, 397-398 10.1016/j.ygyno.2014.11.032
68. Banno, E.; Togashi, Y.; Kobayashi, Y.; Hayashi, H.; Mitsudomi, T.; Nishio, K. Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion Anticancer Res. 2015, 35, 2005-2008
69. Xia, G.; Chen, W.; Zhang, J.; Shao, J.; Zhang, Y.; Huang, W.; Zhang, L.; Qi, W.; Sun, X.; Li, B.; Xiang, Z.; Ma, C.; Xu, J.; Deng, H.; Li, Y.; Li, P.; Miao, H.; Han, J.; Liu, Y.; Shen, J.; Yu, Y. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles J. Med. Chem. 2014, 57, 9889-9900 10.1021/jm5014659
70. Bryan, M. C.; Burdick, D. J.; Chan, B. K.; Chen, Y.; Clausen, S.; Dotson, J.; Eigenbrot, C.; Elliott, R.; Hanan, E. J.; Heald, R.; Jackson, P.; La, H.; Lainchbury, M.; Malek, S.; Mann, S. E.; Purkey, H. E.; Schaefer, G.; Schmidt, S.; Seward, E.; Sideris, S.; Wang, S.; Yen, I.; Yu, C.; Heffron, T. P. Pyridones as highly selective, noncovalent inhibitors of T790M double mutants of EGFR ACS Med. Chem. Lett. 2016, 7, 100-104 10.1021/acsmedchemlett.5b00428
71. Miyadera, K.; Kato, M.; Takahashi, I.; Ito, K.; Aoyagi, Y.; Fukasawa, K.; Sagara, T.; Yonekura, K.; Iwasawa, Y.; Utsugi, T. TAS-2913 is a mutant selective EGFR inhibitor for NSCLC: characterization against EGFR T790M in cell and xenograft models Eur. J. Cancer 2012, 48 (Suppl. 6) 44 10.1016/S0959-8049(12)71940-8
72. Kato, M.; Miyadera, K.; Ito, K.; Aoyagi, Y.; Hashimoto, A.; Yonekura, K.; Iwasawa, Y.; Utsugi, T. TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling Eur. J. Cancer 2014, 50, 128 10.1016/S0959-8049(14)70527-1
73. Kato, M.; Miyadera, K.; Shibata, Y.; Ito, K.; Aoyagi, Y.; Chiba, M. Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity Mol. Cancer Ther. 2013, 12, C112 10.1158/1535-7163.TARG-13-C112
74. Ito, K.; Miyadera, K.; Aoyagi, Y.; Kato, M.; Kato, M.; Yonekura, K.; Iwasawa, Y.; Utsugi, T. Abstract C111: In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI Mol. Cancer Ther. 2013, 12, C111 10.1158/1535-7163.TARG-13-C111
75. Kim, D. W.; Lee, D. H.; Kang, J. H.; Park, K.; Han, J. Y.; Lee, J. S.; Jang, I. J.; Kim, H. Y.; Son, J.; Kim, J. H. Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). Presented at the ASCO Annual Meeting, Chicago, IL, May 31, 2014; Abstract 8010.
76. Kim, D. W. HM61713, an EGFR-mutant selective inhibitor Ann. Oncol. 2015, 26, ii14 10.1093/annonc/mdv088.2
77. Mao, L.; Pan, W.; Wang, X.; Zhang, Y.; Li, R.; Waykole, L.; Sethuraman, V. Preparation of polymorphic forms of 1,2-disubstituted 7-chloro-1H-benzo[d]imidazol compound as EGFR inhibitors. WO2015085482A1, 2015.
78. Kasibhatla, S.; Li, J.; Tompkins, C.; Vaillancourt, M. T.; Anderson, J.; Pferdekamper, A. C.; Li, C.; Long, O.; McNeill, M.; Epple, R.; Liao, D.; Murphy, E.; Bender, S.; Jia, Y.; Lelais, G. EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC. Presented at the AACR Annual Meeting, San Diego, CA, April 5-9, 2014; Abstract 1733.
79. Tan, D. S. W.; Seto, T.; Leighl, N. B.; Riely, G. J.; Sequist, L. V.; Felip, E.; Wolf, J.; Yang, J. C. H.; Matushansky, I.; Yu, X.; Schmitz, S. F. H.; Cui, X.; Kim, D. W. First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. Presented at the ASCO Annual Meeting, Chicago, IL, May 29-June 2, 2015; Abstract 8013.
80. Xu, X. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance Chin. J. Cancer 2015, 34, 1-3 10.1186/s40880-015-0029-3
81. Goto, Y.; Nokihara, H.; Murakami, H.; Shimizu, T.; Seto, T.; Krivoshik, A. P.; Keating, A. T.; Uegaki, K.; Takeda, K.; Komatsu, K.; Morita, S.; Fukuoka, M.; Nakagawa, K. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. Presented at the ASCO Annual Meeting, Chicago, IL, May 29-June 2, 2015; Abstract 8014.
82. Ercan, D.; Choi, H. G.; Yun, C. H.; Capelletti, M.; Xie, T.; Eck, M. J.; Gray, N. S.; Jänne, P. A. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors Clin. Cancer Res. 2015, 21, 3913-3923 10.1158/1078-0432.CCR-14-2789
83. Thress, K. S.; Paweletz, C. P.; Felip, E.; Cho, B. C.; Stetson, D.; Dougherty, B.; Lai, Z.; Markovets, A.; Vivancos, A.; Kuang, Y.; Ercan, D.; Matthews, S. E.; Cantarini, M.; Barrett, J. C.; Jänne, P. A.; Oxnard, G. R. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M Nat. Med. 2015, 21, 560-562 10.1038/nm.3854
84. Woyach, J. A.; Furman, R. R.; Liu, T. M.; Ozer, H. G.; Zapatka, M.; Ruppert, A. S.; Xue, L.; Li, D. H.; Steggerda, S. M.; Versele, M.; Dave, S. S.; Zhang, J.; Yilmaz, A. S.; Jaglowski, S. M.; Blum, K. A.; Lozanski, A.; Lozanski, G.; James, D. F.; Barrientos, J. C.; Lichter, P.; Stilgenbauer, S.; Buggy, J. J.; Chang, B. Y.; Johnson, A. J.; Byrd, J. C. Resistance mechanisms for the Brutoǹs tyrosine kinase inhibitor ibrutinib N. Engl. J. Med. 2014, 370, 2286-2294 10.1056/NEJMoa1400029